ArticleStem cell research & therapy2025
Efficacy and safety of intrathecal human umbilical cord-derived mesenchymal stromal cell therapy for bone cancer pain: a preclinical study.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Needle gauge and length effects on human stem cell viability during injection: a comprehensive review.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBone cancer pain (BCP) is a severe complication in patients with advanced cancer, for which current therapies remain inadequate and often lead to significant adverse effects. Mesenchymal stromal cell (MSC)-based therapy has recently emerged as a promising strategy for pain management. However, the safety profile of MSC therapy for BCP treatment has not yet been verified in preclinical studies.
methodsIn this study, clinical-grade human umbilical cord-derived MSCs (hUC-MSCs) at doses of 1 × 10⁶ or 4 × 10⁶ were administered intrathecally to BCP rats to evaluate analgesic efficacy, acute toxicity, and in vivo biodistribution. Additional assessments in nude mice investigated the tumorigenicity and tumor-promoting potential of hUC-MSCs.
resultsIntrathecal administration of hUC-MSCs effectively alleviated mechanical allodynia, heat hyperalgesia, spontaneous flinching, and gait abnormalities in BCP rats, while attenuating hyperactivation of neurons and glial cells in the spinal dorsal horn. The higher dose of 4 × 10⁶ hUC-MSCs demonstrated superior analgesic efficacy compared to the 1 × 10⁶ dose. Importantly, comprehensive safety evaluations confirmed a favorable preclinical safety profile for intrathecal hUC-MSC administration, demonstrating absence of acute toxicity, restricted distribution, and no tumorigenicity or tumor-promoting potential.
conclusionsIntrathecal hUC-MSC therapy demonstrates marked analgesic efficacy and a favorable safety profile in BCP, showing strong potential for clinical translation. This preclinical study provides compelling evidence to support future clinical trials and therapeutic applications of hUC-MSC therapy for BCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.